Coulter Partners is a board and senior level global executive search specialist focused exclusively on Life Sciences. We work closely with those at the cutting edge of innovation in the industry to understand their challenges. With an extensive global network and expertise gained over 25 years in the sector, we have become trusted advisers on leadership in the pharmaceuticals, biotechnology, medical technology, diagnostics, health tech, CRO and services sectors. We also work closely with the global investor community, hiring for their own teams as well as building the boards and executive leadership teams of their portfolio companies. The largest and fastest growing dedicated Life Science search firm, our team of 95 completes over 260 assignments a year working from 14 offices across UK, EMEA, USA & APAC. We share knowledge and connections across the globe, as one team with one goal. To bring our clients the world’s best talent.
At the heart of everything they do Coulter Partners is an exceptional team of talented individuals. Multi-disciplined, passionate and committed to being the best, they have PhDs, MBAs and speak many languages. Every challenge is approached with a blend of innovative thinking and best-in-class search methodology. There are no barriers to sharing information and everyone is rewarded for quality delivery. Exchanging knowledge, experience and data brings mutual support. Success follows naturally.
Coulter Partners is a global search specialist focused exclusively on life sciences. The firm is held in the highest regard as trusted adviser to the sector on senior leadership roles in the American, U.K. and European Markets.
Life sciences search specialist Coulter Partners has placed Brian O’Callaghan as chief executive officer of ObsEva, a clinical-stage biopharmaceutical company developing and commercializing novel therapies for women’s reproductive health. Client partner Nona Footz led the assignment. Mr. O’Callaghan succeeds Ernest Loumaye, who co-founded the firm in 2012. As ObsEva evolves from a development company toward
Life sciences search specialist Coulter Partners has formed a partnership with BioInnovation Institute (BII), the international incubator in Denmark for research-based innovation and entrepreneurship. The firm has been engaged to provide support for BII across three workstreams: providing assessment, coaching and development for the CEOs of start-up businesses in BII’s portfolio under the Creation House
The demand for talent in the life sciences sector has fueled continued growth at global executive search firm Coulter Partners. In many ways, the global pandemic has expanded the need for skilled leaders across the sector. To help manage its growth, the firm recently hired Marianne McNamara as operations director for the U.S. Also joining
Over the past few months, numerous healthcare organizations have turned to executive search firms to find new chief medical officers. In the era of COVID-19 we can expect this to be another burgeoning area for executive search firms. Life sciences-focused search firm Coulter Partners recently assisted Sequana Medical in the recruitment of Oliver Gödje as its new
(Aug. 27, 2020) Coulter Partners was very pleased to partner once again with Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, to secure the appointment of Jason A. Amello as Chief Financial Officer. Jason will be based in the U.S. and will support Saniona’s advancement of late-stage clinical trials with lead
(Aug. 20, 2020) Coulter Partners was very pleased to partner recently with Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, to secure the appointment of Oliver Gödje, MD, PhD, as Chief Medical Officer. Dr Gödje replaces Gijs Klarenbeek, MD, who remains
(July 28, 2020) Coulter Partners was delighted to partner recently with Optimapharm to secure the appointment of Dr. Andrew Copestake as Chief Executive Officer. Andrew joins Optimapharm’s executive management team following several months advising the company’s Board of Directors. Optimapharm is a contract research organization managing clinical trials on behalf of leading biotech, pharma and
(June 20, 2020) Coulter Partners was delighted to partner recently with Pharming Group N.V. (Euronext Amsterdam: PHARM), to secure the nomination of Barbara Yanni and Mark Pykett to the Board of Supervisory Directors. An Extraordinary General Meeting of Shareholders is expected to be convened later this year for their official appointment. Until that moment, Barbara
LONDON, UK., January 2020 – Coulter Partners was delighted to partner recently with Stilla Technologies, provider of pioneering digital PCR (dPCR) solutions for high-precision genetic analysis, to secure the appointment of Khaled Bahi as Chief Financial Officer. His appointment comes at a time of rapid growth for the company, with the recent opening of a U.S.